DF/HCC Program Affiliation

Head and Neck Cancer

Research Abstract

Dr. Haddad’s current research activity involves the use of intensive and Novel chemoradiotherapy regimens for patients with locally advanced and metastatic head and neck cancer with particular attention to radioprotection. He is also the principal investigator in a large national phase III study comparing sequential chemoradiotherapy to concomitant chemoradiotherapy: The Paradigm Trial. Other initiatives currently ongoing include collaboration with the NCI/CTEP in a phase II study looking at the use of depsipeptide in head and neck cancer, as well as looking at new molecules in head and neck cancer treatment such as Cetuximab and Zactima. Dr. Haddad lectures extensively on head and neck cancer, both on the regional, national, and international level.

Publications

• Sonis S, Haddad R, Posner M, Watkins B, Fey E, Morgan TV, Mookanamparambil L, Ramoni M.Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated fo
  16920386
• Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner M.Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck
  16785415
• Haddad R, Allen A, Wirth L, Tishler R, Posner M.Integrating novel agents into the curative treatment of head and neck cancer.Expert Rev Anticancer Ther 2006 Feb;6(2):157-9.
  16445367